Bluebird Bio (BLUE) announced that it will proceed with a 1-for-20 reverse stock split of the company’s common stock following approval by both its Board of Directors and BLUE stockholders at its reconvened annual meeting held on December 4, 2024. As previously announced, the primary goal of the Reverse Stock Split is to increase the per share market price of the company’s common stock to regain compliance with Nasdaq’s minimum bid price requirement for continued listing. The Reverse Stock Split is expected to become effective at 5 p.m., Eastern Time, on December 12, 2024. The common stock is expected to begin trading on a split-adjusted basis when the markets open on December 13, 2024, under the existing trading symbol “BLUE”. The new CUSIP number for the common stock following the Reverse Stock Split will be 09609G 209.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLUE:
- Bluebird Bio participates in CMMI Cell and Gene Therapy Access Model
- Largest borrow rate increases among liquid names
- FDA investigating serious risk of hematologic malignancy following Skysona
- Morgan Stanley, Comerica upgraded: Wall Street’s top analyst calls
- Bluebird Bio downgraded to Neutral at BofA on slower expected Lyfgenia ramp